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Clinical and Population Studies
Is Sticky Blood Bad for the Brain?
Hemostatic and Inflammatory Systems and Dementia in the Caerphilly
Prospective Study
John Gallacher, Antony Bayer, Gordon Lowe, Mark Fish, Janet Pickering, Sofia Pedro, Frank Dunstan,
James White, John Yarnell, Yoav Ben-Shlomo
Objective—Hemostasis and inflammation have been implicated in dementia. This study investigates the role of specific
hemostatic and inflammatory pathways with incident vascular and nonvascular dementia.
Methods and Results—This was a prospective study of a population sample of men aged 65 to 84 years, with baseline
assessment of hemostatic and inflammatory factors and cognition measured 17 years later. The sample included
865 men (59 had dementia and 112 had cognitive impairment, not dementia), free of vascular disease at baseline
and for whom hemostatic and inflammatory marker data were available and cognitive status was known. A total
of 15 hemostatic and 6 inflammatory markers were assessed. Factor analysis was used to identify hemostatic
subsystems. The National Institute of Neurological Disorders and Stroke–Association Internationale pour la
Recherche et l’Enseignement en Neurologie criteria were used to identify vascular dementia. By using standardized
(z) scores for hemostatic and inflammatory markers, and after adjustment for age and risk factors, vascular
dementia was associated with fibrinogen (hazard ratio [HR], 1.68; 95% confidence interval [CI], 1.02–2.76), factor
VIII (HR, 1.79; 95% CI, 1.09 –3.00), and plasminogen activator inhibitor 1 (HR, 3.13; 95% CI, 1.73–5.70). For
vascular dementia, the HR risk from high levels of all three hemostatic variables (fibrinogen, factor VIII, and
plasminogen activator inhibitor 1) was 2.97 (P0.001). Inflammatory factors were not associated with vascular
dementia.
Conclusion—The associations of these hemostatic markers with vascular dementia may implicate clot formation as the
primary mechanism and are consistent with a microinfarct model of vascular dementia. (Arterioscler Thromb Vasc
Biol. 2010;30:599-604.)
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Hemostasis and the inflammatory response are complexand interrelated processes that are associated with a
variety of phenotypes, including cardiovascular diseases.1
There is limited case-control evidence associating markers of
hemostasis and inflammation with dementia.2–6 Limited pro-
spective data come from the Rotterdam Study, which found
that fibrinogen, but not C-reactive protein (CRP), was asso-
ciated with incident dementia at the age of 6 years.7 There-
fore, further studies of hemostatic and inflammatory markers
and risk of dementia (both vascular and nonvascular) are
required.
See accompanying article on page 461
Hemostasis involves a delicate balance of several closely
related subsystems or pathways. It is possible, therefore, that
associations with these responses reflect the impact of spe-
cific pathways rather than of individual biomarkers. One area
of interest is whether hemostatic markers can be analyzed
within the context of the coagulation pathways that they
represent and whether these pathways can be used to identify
more closely the mechanisms associated with cognitive im-
pairment. In the Caerphilly Prospective Study, a wide range
of available hemostatic markers allows the comparative
influence of several pathways to be assessed.8
Methods
The Study Population
Between 1979 and 1983, all men aged 45 to 59 years within the
locality of Caerphilly in South Wales, England, were invited to
participate. Of the 2818 men found eligible, 2512 (89.1%) were
recruited. For the second examination (1985), the original cohort was
supplemented with all men of a similar age who had moved into the
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area since the first examination. A total of 2398 men were seen and
provided blood samples.8 Data on hemostatic and inflammatory
markers were available for 2318 men. Not all the hemostatic and
inflammatory markers were assessed for all men, because of pro-
gressive depletion of stored plasma samples.9
At the third (1993), fourth (1996), and fifth (2004) examinations,
cognition was assessed. At the fifth examination, when the men were
aged 65 to 84 years, cognitive assessment was used to identify men
eligible for neurological examination to ascertain dementia. In-
formed consent was obtained from every participant, and the study
was approved by the Gwent Research Ethics Committee.
Hemostatic and Inflammatory Markers
A fasting blood sample was obtained during the second examination.
In a sample anticoagulated with potassium EDTA, fibrinogen was
measured using heat precipitation nephelometry; plasma viscosity,
with a Coulter-Harkness capillary viscometer; white blood cell
count, in an automated cell counter; and 2-macroglobulin and
1-antitrypsin, as previously described.8
Activated partial thromboplastin time, activated protein C ratio,
fibrinogen, factor VII, and factor VIII (FVIII) were assayed in an
MDA-180 coagulometer (Organon Teknika, Cambridge, England).8
Fibrin formation time and reaction clotting time were measured by
thromboelastography.10 Activated factor XII, prothrombin fragment
12 (Frag12), thrombin-antithrombin complexes, tissue plasmin-
ogen activator antigen, von Willebrand factor antigen (VWF), and
fibrin D-dimer were assayed by enzyme-linked immunosorbent
assay8,11; and plasminogen activator inhibitor 1 (PAI-1) was assayed
using a chromogenic assay.8 High-sensitivity CRP was assayed by
immunonephelometry.8 Interleukin 6 (IL-6) was assayed using a
high-sensitivity enzyme-linked immunosorbent assay.11
Ascertainment of Dementia
Cognitive screening at the fifth examination was used to identify
men eligible for a neurological examination.12 The criteria were as
follows: all men whose Cambridge Cognitive Examination score was
lower than 83 or whose decline in Cambridge Cognitive Examination
score between any two cognitive assessments was greater than 10
points or who were unable to complete the CAMCOG were eligible
for a neurological examination. For nearly all men, the neurological
examination occurred within two months of cognitive screening.
The criteria for dementia and cognitive impairment not dementia
(CIND) are detailed elsewhere.12 Briefly, the neurological examina-
tion included the Cambridge Mental Disorders of the Elderly
Examination, a cardiovascular and neurological examination13; the
Rosen-Modified Hachinski Ischaemic Score (HIS)14; the Frontal
Assessment Battery15; and the Clinical Dementia Rating.16 With the
subject’s consent, someone who knew him or her well (usually the
next of kin) was identified and approached to complete an Informant
Questionnaire on Cognitive Decline in the Elderly and the modified
Cambridge Mental Disorders of the Elderly Examination informant
interview.17 Additional questions were asked when appropriate about
symptom onset and progression. All available general practitioner
and hospital records were reviewed and summarized, with particular
attention given to mention of patients’ mental state and relevant
investigations. All subjects who had died were identified by “flag-
ging” at the National Health Service Central Register in Southport,
and their cause of death was noted. Further information was sought
on those with a cause of death recorded as dementia or Alzheimer’s
disease (AD). Subjects with vascular dementia were required to fulfil
National Institute of Neurological Disorders and Stroke–Association
Internationale pour la Recherche et l’Enseignement en Neurologie
criteria for possible or probable vascular dementia.18 Subjects not
meeting the full dementia criteria and with an HIS of 3 or higher
(including history of cerebrovascular disease or consistent lateraliz-
ing neurological signs) were classified as having vascular CIND.12
Subjects who fulfilled the National Institute of Neurological and
Communicative Disorders–Alzheimer’s Disease and Related Disor-
ders Association criteria for probable AD19 and who had no clinical
features suggestive of cerebrovascular disease (HIS 2 and absence
of vascular disease on available neuroimaging) or other causative
disorder were classified as having AD. Subjects with a presentation
or clinical course in keeping with AD and features to suggest
cerebrovascular disease (operationalized as an HIS 3 or neuroim-
aging evidence of infarction) were diagnosed as having mixed
dementia.20 Subjects fulfilling the standardized diagnostic criteria for
other dementia-like conditions were categorized accordingly. Sub-
jects with CIND were classified by cause only if likely cause was
apparent. Because of small numbers, all nonvascular conditions were
combined for the purpose of analysis.
Statistical Analysis
Hemostatic and inflammatory markers were log transformed where
appropriate, and all markers were standardized (ie, z scores were
calculated). Associations of individual biomarkers with dementia
and CIND were performed by Cox regression (STATA 10 software;
Statacorp, Tex). Adjustment was made for age, social class, systolic
blood pressure, body mass index, smoking status (never smoked,
ex-smoker, or current smoker), total cholesterol level, and alcohol
consumption. Men with previous vascular disease, intermittent
claudication, or stroke were not included. Analyses were repeated
adjusting for premorbid cognitive function using the National Adult
Reading Test score obtained at the third examination. The Registrar
General’s classification of social class is a definition of socioeco-
nomic status widely used in England. Social class was modeled as a
4-level indicator variable composed of these levels: I and II, III
nonmanual, III manual, and IV and V. To investigate the possibility
of a prodromal effect of dementia, Cox regressions were repeated,
not including men with evidence of early cognitive decline. Evidence
of early cognitive decline was defined as cognitive scores declining
consistently from the first cognitive examination.21 This is a strong
test of the prodromal hypothesis; however, it excludes men whose
decline began soon after baseline (second) examination and men
whose decline is not the result of a dementing process.
To test the hypothesis that associations with individual biomarkers
reflect the operation of specific coagulation pathways on vascular
dementia, structural equation modeling (SEM) was used. SEM
allows variables to act dependently and independently and enables
the putative causal pathway to be modelled. A two-step procedure
was used. First, specific coagulation pathways were identified by
exploratory factor analysis. Structural modelling (using EQS soft-
ware) was then used to estimate the association between the latent
variables representing specific coagulation pathways and dementia.
The fit statistics used to evaluate the fit of the data to the
hypothesized coagulation pathways and dementia were the compar-
ative fit index (CFI), the root mean square error of approximation
(RMSEA), and the standardized root mean square residual (SRMR).
The SEM glossary describes the coefficients that are shown (Figure).
These are as follow: (1) standardized path coefficients (single-
headed arrows) that are standardized regression coefficients and
indicate the association between dependent and independent vari-
ables, (2) standardized residual covariances (double-headed arrows)
indicating associations between independent variables not accounted
for in the model, and (3) standardized residual variances (adjacent to
independent variables) indicating measurement error for the ob-
served independent variables. An introduction to SEM is provided as
electronically available supplementary material (available online at
http://atvb.ahajournals.org).
Results
Of the 2318 men with data on hemostatic and inflammatory
markers, 750 were known to have died before the current phase
of the study, leaving 1568 considered to be alive; 1429 of these
men were eligible for follow-up, with 1137 (79.6%) successfully
followed up and cognitively screened. Of these men, 71 were
diagnosed as having dementia, 171 were diagnosed as having
CIND, and 895 were cognitively healthy. A further 21 men were
diagnosed as having dementia from medical records, resulting in
the cognitive status being available for 1158 men. Of these men,
600 Arterioscler Thromb Vasc Biol March 2010
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865 were free of vascular disease at baseline and available for
analysis, of whom 112 had cognitive impairment and 59 had
dementia. If men with evidence of early decline are omitted, 744
were available for analysis, of whom 85 were cognitively
impaired and a further 42 had dementia. The maximum
follow-up was 20 years; however, it averaged 17.3 years (SD,
1.3 years). For the exploratory factor analysis, 476 men had
complete data for all hemostatic variables. For structural mod-
eling, 602 men had complete data.
The baseline characteristics of the 1568 men who were
alive at the beginning of the study show that men who were
not followed up were more likely to be of manual social class
(34.8% vs 62.0%; P0.01) and more likely to be current
smokers (44.5% vs 35.9%; P0.01) and to have a lower
cognitive function (National Adult Reading Test mean, 21 vs
25; P0.01). They did not differ significantly in age or body
mass index, and any differences in blood pressure were small.
Regarding hemostatic markers, all differences were slight,
with men who were not followed up having a longer activated
partial thromboplastin time (mean, 33.4 vs 32.9 seconds;
P0.04) and higher levels of D-dimer (mean, 82.2 vs 78.0
ng/mL; P0.05), factor XIIa (mean, 3.23 vs 3.02 ng/mL;
P0.04), and tissue plasminogen activator antigen (mean,
11.9 vs 11.2 ng/mL; P0.01). Men who were not followed
up also had slightly higher levels of the inflammatory
markers 2-macroglobulin (mean, 15.7 g/100 g vs 15.2
g/100g; P0.03) and 1-antitrypsin (mean, 16.7 g/100 g vs
16.1 g/100 g; P0.01) and substantially higher levels of IL-6
(mean, 4.91 vs 2.20 pg/mL; P0.01). The following markers
required log transformation for the analysis: D-dimer,
Frag12, thrombin-antithrombin complex, VWF, plasma
viscosity, CRP, IL-6, and 2-macroglobulin.
Associations with cognitive impairment (CIND and de-
mentia) were investigated in 865 men free of vascular disease
at baseline (Table 1). After adjustment for age, social class,
systolic blood pressure, body mass index, smoking status,
total cholesterol level, and alcohol consumption, an associa-
tion with vascular impairment was found for fibrinogen.
Evidence of association was also found for PAI-1. There was
no evidence of association with any of the inflammatory
markers. For nonvascular impairment, there was no evidence
of increased risk with any of the hemostatic markers or
inflammatory markers, although factor VII appeared to have
a protective effect.
The analysis was repeated for dementia. For the hemostatic
markers, vascular dementia was associated with fibrinogen,
FVIII, and PAI-1. The analysis was repeated, excluding men
with evidence of early cognitive decline. The smaller num-
bers reduced the power of the analysis, but the point estimates
were closely comparable to those found in the sample as a
whole, with the strongest associations being found for fibrin-
ogen (hazard ratio [HR], 1.79; 95% confidence interval [CI],
0.98-3.28; P0.06), FVIII (HR, 1.77; 95% CI, 0.88–3.57;
P0.11), and PAI-1 (HR, 2.68; 95% CI, 1.22–5.88; P0.04).
For nonvascular dementia, evidence of a protective associa-
tion was found for the hemostatic marker Frag12 and for
the inflammatory marker plasma viscosity.
The associations of FVIII, fibrinogen, and PAI-1 with
vascular dementia may either reflect a general effect of the
coagulation cascade or identify specific coagulation pathways
that confer increased risk. These alternatives were investi-
gated by including FVIII, fibrinogen, and PAI-1 in the same
analysis to show whether their effects were independent of
one another. The presence of a general hemostatic effect
would be indicated by the absence of independent associa-
tions. The analysis was consistent with each biomarker
making some independent contribution to the association:
fibrinogen, HR, 2.11 (95% CI, 0.88–5.04; P0.09); FVIII,
HR, 2.09 (95% CI, 1.02–4.31; P0.04); and PAI-1, HR, 4.39
(95% CI, 1.97–9.77; P0.001). The combined independent
effects of these biomarkers on risk for vascular dementia was
2.97 (95% CI, 1.38–4.56; P0.001).
The SEM was used to further investigate the relative
contribution to risk of vascular dementia of the coagulation
pathways represented by the available hemostatic markers.
Exploratory factor analysis found four statistical factors
corresponding to components of the coagulation pathway
(Table 2). The high loadings on statistical factor 1 of FVIII
(0.88) and VWF (0.82) were interpreted to represent the
FVIII/VWF complex (indicating potential for platelet and
fibrin plug formation). High loadings on statistical factor 2 of
PAI-1 (0.80) and tissue plasminogen activator antigen (0.75)
were interpreted to represent the potential for impaired
fibrinolytic activity. High loadings on statistical factor 3 of
fibrinogen (0.81) and D-dimer (0.69) were interpreted to
represent clotting activity. High loadings on statistical factor
four of thrombin-antithrombin complexes (0.75) and
Frag12 (0.77) were interpreted to represent thrombin
generation. These statistical factors were used as latent
variables for the purposes of structural modeling.
The four-factor structural model (Figure), using the two
highest loading biomarkers per latent variable as identified in
the exploratory factor analysis (Table 2, boldface), provided
a poor fit to the data (N524, 22283.46, P0.001,
Figure. Structural equation modeling analysis of hemostatic
pathways.
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CFI0.90, RMSEA0.07, SRMR0.06) and simpler mod-
els were sought. The best-fitting model used five observed
variables (yellow background) and included two latent vari-
ables (pink background) (N602, 265.27, P0.51,
CFI1.00, RMSEA0.01, SRMR0.015), explaining 3.5%
of the variance in vascular dementia (Figure). The analysis
indicated that the latent variables FVIII/VWF complex
(.05, P0.05) and clot formation and lysis (.15,
P0.05) were associated with vascular dementia. The
observed variable PAI-1 was also independently associated
with vascular dementia (.08, P0.05). If this analysis
is repeated using just the five observed variables with
no latent variables, the model fit is poor (N602,
210426.59, P0.001, CFI0.03, RMSEA0.26,
SRMR0.17).
Discussion
In this 17-year prospective study, hemostatic rather than
inflammatory markers have been shown to predict vascular
cognitive impairment and vascular dementia. Specifically,
fibrinogen, FVIII, and PAI-1, representing the coagulation
pathways of clotting activity, platelet and fibrin plug forma-
tion, and fibrinolytic potential, were identified as increasing
the risk of vascular dementia.
Strengths and Limitations
High levels of participation have been achieved throughout
the study, although the sample was composed of men only.
The sample used herein reflects an 80% response rate.
Diagnosis of cognitive status was obtained through examina-
tion of participants and medical records using standard
criteria. Hemostatic factors were assayed using standard
techniques, and internal laboratory quality assurance was
evaluated.8,11 Adjustment for a wide range of potential con-
founding variables was made. Cognitive status was not available
at baseline, but adjustment was made for premorbid cognitive
function assessed within 5 years of baseline. Men who were not
followed up were more likely to have higher levels of some
biomarkers and were more likely to be manual social class, to be
current smokers, and to have lower cognitive function. These
Table 1. Associations of Individual Hemostatic and Inflammatory Markers With Cognitive Impairment and Dementia in 865 Men Free
of Vascular Disease and Not Taking Anticoagulants at Baseline*
Type of Marker
Vascular Impairment
(n53)
Non Vascular Impairment
(n133)
Vascular Dementia
(n27)
Non Vascular Dementia
(n26)
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Hemostatic
Fibrinogen 1.41 (1.01–1.98) 0.04 1.06 (0.80–1.26) 0.99 1.68 (1.02–2.76) 0.04 0.77 (0.47–1.28) 0.30
Factor VII 1.05 (0.74–1.50) 0.80 0.74 (0.55–1.00) 0.046 0.98 (0.61–1.55) 0.90 0.86 (0.50–1.47) 0.60
Factor VIII 1.35 (0.92–1.98) 0.10 0.88 (0.67–1.14) 0.30 1.79 (1.09–3.00) 0.02 0.96 (0.62–1.48) 0.90
von Willebrand factor antigen 1.16 (0.82–1.65) 0.40 0.93 (0.75–1.17) 0.50 1.26 (0.77–2.05) 0.40 1.03 (0.66–1.60) 0.90
von Willebrand factor activity 1.12 (0.79–1.60) 0.50 0.99 (0.80–1.23) 0.90 1.32 (0.79–2.20) 0.30 0.99 (0.66–1.47) 0.99
Factor XIIa 1.11 (0.74–1.66) 0.60 0.87 (0.64–1.18) 0.40 0.96 (0.53–1.73) 0.90 0.90 (0.52–1.57) 0.70
Activated partial
thromboplastin time
1.14 (0.87–1.49) 0.30 1.04 (0.83–1.31) 0.70 1.12 (0.87–1.45) 0.40 1.23 (0.89–1.71) 0.20
Activated protein C ratio 0.89 (0.61–1.31) 0.60 1.18 (0.86–1.62) 0.30 0.97 (0.55–1.68) 0.90 1.31 (0.72–2.37) 0.40
Reaction clotting time 1.07 (0.76–1.50) 0.70 0.92 (0.73–1.15) 0.40 1.08 (0.81–1.44) 0.60 0.98 (0.65–1.49) 0.90
Fibrin clotting time 1.10 (0.82–1.49) 0.50 1.05 (0.84–1.31) 0.70 0.90 (0.48–1.68) 0.70 1.04 (0.69–1.56) 0.90
Fragment 12 0.89 (0.56–1.41) 0.60 0.88 (0.63–1.23) 0.40 0.71 (0.41–1.24) 0.20 0.51 (0.26–0.98) 0.04
Thrombin-antithrombin
complex
0.87 (0.51–1.48) 0.60 1.12 (0.83–1.50) 0.50 0.75 (0.38–1.50) 0.40 0.79 (0.45–1.39) 0.40
Tissue plasminogen activator 1.00 (0.68–1.46) 0.99 0.90 (0.71–1.14) 0.40 1.45 (0.84–2.51) 0.20 0.95 (0.58–1.55) 0.80
Plasminogen activator
inhibitor
1.77 (1.13–2.77) 0.01 1.18 (0.88–1.60) 0.30 3.13 (1.73–5.70) 0.001 1.43 (0.77–2.66) 0.30
D-dimer 0.99 (0.72–1.33) 0.90 1.10 (0.87–1.39) 0.40 1.09 (0.74–1.62) 0.70 1.18 (0.76–1.87) 0.50
Acute-phase inflammatory
response
Plasma viscosity 1.18 (0.80–1.76) 0.40 0.95 (0.75–1.21) 0.70 1.42 (0.82–2.47) 0.07 0.55 (0.31–0.96) 0.03
2-Macroglobulin 0.86 (0.58–1.29) 0.50 1.08 (0.85–1.37) 0.60 0.68 (0.36–1.29) 0.20 0.99 (0.57–1.73) 0.99
1-Antitrypsin 1.04 (0.71–1.52) 0.80 0.91 (0.71–1.17) 0.50 1.14 (0.65–2.00) 0.60 1.33 (0.82–2.17) 0.30
White blood cell count 0.95 (0.63–1.44) 0.80 0.92 (0.71–1.19) 0.50 1.40 (0.80–2.42) 0.20 0.70 (0.42–1.19) 0.20
C-reactive protein 1.04 (0.66–1.64) 0.90 0.97 (0.74–1.28) 0.90 1.29 (0.69–2.40) 0.40 0.78 (0.42–1.44) 0.40
Interleukin 6 0.90 (0.54–1.49) 0.70 0.87 (0.63–1.21) 0.40 1.05 (0.54–2.04) 0.90 0.66 (0.32–1.35) 0.30
CI indicates confidence interval; HR, hazard ratio.
*Data adjusted for age, social class, systolic pressure, body mass index, smoking, total cholesterol, and alcohol consumption.
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biases indicate that the current analysis is likely to be conserva-
tive. The use of SEM to explore the effect of specific hemostatic
pathways is limited to the variables available to the study and
does not represent the influence of the coagulation cascade as a
whole. Although SEM generated a biologically plausible anal-
ysis, the analysis requires confirmation elsewhere. Although
sufficiently powered for its intended purpose, the study is small
for the present purpose. Despite this, consistent and robust
associations were found. However, much larger studies are
required for precise estimates of risk to be available.
Interpretation
These analyses address two basic mechanisms that may be
related to risk of dementia: inflammation and coagulation.
The hypothesis that inflammatory processes increase risk of
nonvascular dementia22, 23 was not supported. This lack of
association may be the result of lack of power or the
nonvascular dementia category, including men with mixed
dementia and men with AD. Alternatively, it may be that
previously reported associations of cognitive decline with
inflammatory markers indicate the effects of incipient demen-
tia.24 An apparently protective effect of plasma viscosity for
nonvascular dementia is anomalous and likely to be a chance
effect.
The hypothesis that hemostasis affects vascular dementia
was strongly supported. Our findings confirm those of several
case-control studies showing that hemostatic markers are
related to vascular dementia in particular,4,6 and dementia in
general.2 Our findings extend this evidence to show prospec-
tively over 17 years that hemostatic markers are associated
with vascular dementia but not nonvascular dementia. Previ-
ous prospective evidence has shown that fibrinogen, but not
CRP, was associated with vascular dementia.7 Our findings
extend this evidence to FVIII, PAI-1, and the inflammatory
marker plasma viscosity.
Of particular interest are the mechanisms by which hemo-
static factors affect risk of vascular dementia. SEM indicated
that coagulation pathways (represented by latent variables)
provided a better model fit than individual biomarkers. Two
coagulation pathways conferred increased risk of vascular
dementia. The association with the latent variable “FVIII/
VWF complex” implicates the formation of the platelet and
fibrin plug, whereas the association with the latent variable
“clot formation and lysis” implicates the formation and lysis
of the fibrin plug. The association of PAI-1 suggests an
additional risk due to impaired fibrinolytic activity. The
relative strengths of these associations suggest that clot
formation and lysis have the major role. The presence of error
covariance linking FVIII/VWF complex and clot formation
and lysis (0.27) is consistent with the association of primary
with secondary hemostasis. In contrast to the findings in the
Rotterdam Study, no independent association was found of
vascular dementia with D-dimer, although D-dimer did con-
tribute to the structural model. The association of impaired
fibrinolytic potential with vascular dementia implicates fibri-
nolysis. Whether this is the result of inhibition of fibrinolysis
by PAI-1 or is a response to higher coagulation levels is
unknown.
Our findings may be attributed to residual confounding.
However, the fact that robust associations are found with
some hemostatic markers and not others, and with vascular
and not nonvascular dementia, argues against this conclusion.
Associations with the hemostatic markers are unlikely to
reflect reverse causality because attenuation by adjustment
for premorbid cognitive function was generally slight and in
some cases the association was strengthened. However, all
three hemostatic markers associated with vascular dementia
are also acute-phase protein reactants.1,25 Therefore, it is
possible that the associations of fibrinogen, FVIII, and PAI-1
with vascular dementia simply reflect associations with other
inflammatory markers rather than associations with hemosta-
sis or fibrinolysis. However, the fact that no association was
found with CRP and IL-6 implicates hemostatic rather than
inflammatory activity. The analyses excluding men with
evidence of early decline demonstrate that a prodromal effect
of vascular dementia on hemostatic factors is unlikely to
account for the associations found.
These data present a picture of vascular dementia being
related to clot formation as the primary mechanism. These
data are consistent with a microinfarction model of vascular
dementia. The small amount of longitudinal data on cognitive
decline supports this conclusion, with some evidence that
D-dimer and fibrinogen are associated with decline in global
function26 and fluid intelligence.27 The clinical implication of
these findings is that reducing clot formation through antico-
agulation is likely to result in greater cognitive benefit than
just the established benefit of a reduction in ischemic stroke,
as suggested in a study of patients with atrial fibrillation.28
However, many of the hemostatic factors identified are
Table 2. Varimax-Rotated Factors From 476 Men With
Complete Hemostatic Marker Data
Hemostatic Marker
Latent Variable
1
(Platelet Plug
Formation) 2 3 4
Fibrinogen 0.05 0.13 0.81 0.05
Factor VII 0.01 0.58 0.09 0.13
Factor VIII 0.88 0.05 0.09 0.01
von Willebrand factor
antigen
0.82 0.05 0.18 0.07
Factor XIIa 0.06 0.36 0.17 0.48
Activated partial
thromboplastin time
0.69 0.06 0.27 0.14
Activated protein C
ratio
0.41 0.20 0.06 0.22
Reaction clotting time 0.13 0.13 0.35 0.01
Fibrin clotting time 0.01 0.06 0.25 0.04
Fragment 12 0.01 0.04 0.11 0.77
Thrombin-antithrombin
complex
0.02 0.13 0.03 0.75
Tissue plasminogen
activator
0.12 0.75 0.09 0.04
Plasminogen activator
inhibitor
0.05 0.80 0.02 0.05
D-dimer 0.17 0.01 0.69 0.28
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acute-phase reactant proteins; similar associations were ob-
served for plasma viscosity and white blood cell count.
Therefore, these associations may also reflect an association
of systemic inflammation with vascular dementia.
In conclusion, specific hemostatic mechanisms, notably
those related to clot formation and lysis, are related to
increased risk of vascular dementia. Further studies are
required, however, to confirm these findings and to establish
whether there is any cognitive benefit from interventions
targeting the clotting process.
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